Introduction
Chronic graft-versus-host disease (C-GVHD) remains the most frequent late complication after allogeneic hematopoietic stem cell transplantation (HSCT) and it represents the major cause of non-relapse mortality and morbidity in long-term survivors. [1] [2] [3] In adults, the reported incidence of C-GVHD ranges between 30 and 50% of HLA-identical sibling transplant recipients, 1 acute GVHD being recognized as the most important factor predicting the development of the chronic form of the disease. [4] [5] [6] The increased use of matched unrelated volunteers as donors 7 and of peripheral blood as stem cell source 8, 9 have led to a further increase of the incidence and severity of this complication.
C-GVHD has been reported to be associated with a graft-versus-leukemia effect (GVL), thus resulting, in the context of transplants for the treatment of hematological malignancies, in a decreased relapse incidence. [10] [11] [12] Nevertheless, the reduced relapse rate could be offset by an increase in transplant-related mortality (TRM) and counterbalanced by a severely impaired quality of life for patients experiencing the extensive form of the disease. 2, 3 Previously published studies documented a lower risk of chronic, as well as of acute GVHD, in younger patients. [4] [5] [6] However, only few studies specifically focused on children. [13] [14] [15] For this reason, risk factors for C-GVHD in childhood are still poorly defined, and few information is available on the GVL effect of this complication, as well as on its impact on disease-free survival (DFS) and TRM of young patients.
We carried out a retrospective analysis on a large number of children receiving allogeneic HSCT from either a matched or mismatched family donor or an unrelated volunteer, in order to identify risk factors predicting the development of C-GVHD and to assess its impact on clinical outcome.
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Patients and methods

Patient characteristics
Six-hundred and ninety-six consecutive patients, given allogeneic HSCT between January were included in this analysis. All new transplants performed were registered yearly by each transplant center, together with the updated follow-up of previously reported transplants, through disease-and transplant-specific data collection forms.
For the purpose of this study, only patients younger than 18 years of age at the time of HSCT and surviving more than 90 days after the graft were considered for data analysis.
Exclusion criteria for the definition of the study population comprised also second or subsequent transplants, the use of a genotypically identical twin as donor and a diagnosis of solid tumor.
In all donor-recipient pairs, histocompatibility was determined by serology for HLA-A, B
and DR antigens, whereas high resolution molecular typing of HLA-class II DRB1 was available for all children given HSCT from an unrelated donor. Four-hundred and fifty (65%) were affected by hematological malignancies, while the remaining 246 children (35%) had a non-malignant disorder. Children with acute leukemia receiving transplantation during first or second complete remission (CR), those with myelodysplastic syndromes (MDS) characterized by a low blast count (i.e. refractory anemia and refractory anemia with ringed sideroblasts), as well as patients with chronic myeloid leukemia (CML) in 1 st chronic phase were considered in early phase, while all other patients with leukemia or MDS were considered in advanced phase. Of the 696 patients analyzed, 418 were males and 278 females. Median age at transplantation was 7 years (range 0.3 -17), whereas median donor age was 12 years (range 0 -55). The donor was an HLA-identical
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GVHD prophylaxis consisted of cyclosporine-A (Cs-A) alone in 343 cases (49%), Cs-A in combination either with methotrexate (MTX) in 127 cases (18%) or with steroids (PDN) in 62 cases (9%). The combination of Cs-A + MTX + in vivo serotherapy (anti-lymphocyte globulin, ALG, or the monoclonal antibody Campath-1G) was adopted for 102 transplants (15%). Nineteen patients (3%) received a T-cell depleted HSCT.
Details on the 696 patients evaluated, as well as on the transplant procedure, are reported in Table 1 .
Diagnosis of acute and chronic GVHD and of chronic GVHD resolution
The diagnosis of acute and C-GVHD was made by the site investigators at each institution on the basis of clinical symptoms, laboratory tests and, whenever possible, on histopathological findings of skin, oral mucosa and gastrointestinal tract. [16] [17] [18] Acute and chronic GVHD were classified according to previously described criteria. 19, 20 In detail, limited C-GVHD was defined as either or both localized skin involvement and hepatic dysfunction due to chronic GVHD, while extensive C-GVHD was defined as generalized skin involvement, or localized skin involvement and/or hepatic dysfunction due to C-GVHD plus: i) liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis, or involvement of eye, or minor salivary glands or oral mucosa, or involvement or any other target organ. 20, 21 Resolution of C-GVHD was defined as the disappearance of all active lesions attributable to C-GVHD (whenever possible confirmed by histopathological findings), and/or normalization of liver function tests, associated with the discontinuation of any form of immunosuppressive treatment.
Treatment of chronic GVHD
The choice among the different options for treatment of C-GVHD was based on the policy in use in each single transplant center and varied over time. In detail, 33 children received a single drug treatment (Cs-A alone in 20 cases, prednisone alone in 11, ursodeoxycolic acid in 1 and monoclonal antibodies in 1 case), while the standard combination of Cs-A and prednisone was used in 62 children, with the addition of azathioprine in 14.
Thalidomide was used, always in combination with Cs-A and/or steroids, in 14 patients.
Fifteen children received 3 or more immunosuppressive drugs. Extracorporeal photochemotherapy was used, as single treatment modality or in combination with other systemic immunosuppressive drugs, in 26 children. 22, 23 Finally, 9 children, all with limited C-GVHD, did not need any specific immunosuppressive therapy.
Statistical analysis
C-GVHD occurrence, as well as DFS, TRM and relapse probability according to C-GVHD occurrence and extension, were calculated by the Kaplan-Meier method; comparisons between probabilities in different patient groups were performed using the log-rank test. 24 As suggested by Pepe et al, 25 C-GVHD was presented, besides the Kaplan-Meier curve, also as the prevalence of C-GVHD over time after transplantation (Figure 1, bottom) . The prevalence function at time t was calculated using the following function (number of patients with C-GVHD at time t) / (number of patients alive and relapse-free at time t). 25, 26 In DFS analysis, both relapse and death in remission due to any cause were considered events, whereas in relapse probability analysis only disease relapse was considered as failure. In TRM analysis, all deaths not due to disease recurrence were considered events.
Results were expressed as probability (%) and 95% confidence interval (95% CI).
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In the univariate analysis of risk factors for C-GVHD development the following variables If the relative event rates (ratio of the observed number of events to the expected number of events in a category, assuming no variation across categories) in two or more adjacent categories (and the mean times-to-event) were not substantially different, these categories were grouped. If no clear pattern was observed for the primary outcome, the median was taken as cut point. 27 For the multivariate analysis of C-GVHD, DFS and relapse probability, the Cox proportional hazard regression model was used, including in the models all the variables with P < 0.05 in univariate analysis. 28, 29 Chi-square test was used to compare differences in percentages.
All P values were 2-sided and values less than 0.05 were considered statistically significant. P values greater than 0.1 were reported as not significant (N.S.), whereas those between 0.05 and 0.1 were reported in detail.
The SAS package (SAS Institute, Cary, NC) was used for the analysis of the data. 
Incidence of chronic GVHD and chronic GVHD resolution
One-hundred and seventy-three (25%) out of the 696 patient analyzed developed C-GVHD at a median of 116 days after transplantation (range 80 -600 days). The limited form of the disease was observed in 109 patients (16%), while extensive C-GVHD was diagnosed in 64 cases (9%). As shown in the top of Figure 1 , two years after the transplant, the overall cumulative probability of C-GVHD was 27% (23 -30). The cumulative probabilities of developing either limited or C-GVHD were 17% (14 -20) and 11% (8 -14) , respectively.
For patients with C-GVHD, median Karnofsky score at time of last follow-up was 90%, with 72 out of the 173 patients (42%) having a Karnofsky score of 100% and only 7 (4%) with a Karnofsky score below 50%.
Skin was the most common target of C-GVHD, being involved in 144 cases (83%), while liver was involved in 49 patients (28%) and the gastro-intestinal tract in 42 (24%). Oral C-GVHD was described in 12 patients (7%), while both eye involvement and joint contractures were reported in 6 cases (3%). Finally, 19 children (11%) had lung involvement from C-GVHD.
The bottom of Figure 1 shows the prevalence of C-GVHD over time after HSCT.
Prevalence was greater during the 1 st year after HSCT, when it reached a value of 18%, while progressively decreased to about 5% at 7 years after transplantation. The prevalence of limited C-GVHD was greater than that of extensive C-GVHD during the first For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 20 months after HSCT, while prevalence of extensive C-GVHD was higher than that of limited C-GVHD from 20 months from C-GVHD afterwards.
C-GVHD resolved in 121 patients (70%), while it was still present at the time of last followup or of death in the remaining 52 children (30%). The median duration of C-GVHD, in the 121 patients in whom this complication resolved, was 5 months (range 1 -93 months). Figure 2 shows the cumulative probability of continuing C-GVHD, that was equal to 16% (6 -25) 8 years after transplantation, and the probability of death with C-GVHD over time after development of the complication, that was 12% (3 -18).
The analysis concerning the impact of C-GVHD therapy on the probability of C-GVHD resolution and on patient's outcome did not show any statistically significant difference among the different treatment modalities (data not shown).
Risk factors for chronic GVHD
A number of demographic and transplant-related characteristics were evaluated as potential risk factors for C-GVHD. Table 2 presents the results of univariate and multivariate analysis of risk factors for development of C-GVHD.
Several variables were strongly associated with an increased risk of C-GVHD in univariate analysis. In particular, older patient age was significantly associated with C-GVHD, with children younger than 5 years having a probability of developing this complication of less than 14%, those with an age from 5 to 15 years a probability of about 30%, and those older than 15 years a probability of 44% (P = 0.0001). Also donor age was a significant risk factor for C-GVHD occurrence in univariate analysis, with a continuous increase in the incidence of this complication from less than 10% for donors younger than 5 years, to more than 40% for donors older than 40 years of age (P = 0.0002). Female donor and male recipient combination was another factor predicting C-GVHD development (34% vs. 23%, P = 0.01). Furthermore, patients affected by hematological malignancies had a For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From greater incidence of C-GVHD (35% vs. 13%, P = 0.01), as well as those treated with TBI (38% vs. 17%, P = 0.0001) and those with previous grade II-IV acute GVHD (45% vs. 14%, P = 0.0001). Cord blood transplants had a significantly lower probability of C-GVHD (3%) as compared to bone marrow or peripheral blood transplants (28%, P = 0.0073). As reported in Table 2 , in our cohort of patients parity of female donors did not show any effect on the risk of C-GVHD development.
In multivariate analysis, the following 6 characteristics resulted associated with an increased probability of developing C-GVHD: patient age 15 years (RR = 1.82, P = 0.03), donor age 5 years (RR = 3.36, P < 0.001), female donor and male recipient (RR = 1.52, P = 0.01), use of total-body irradiation (TBI) as part of the conditioning regimen (RR = 1.56, P = 0.02), diagnosis of hematological malignancy (RR = 1.80, P = 0.01) and, with the highest relative risk, previous grade II-IV acute GVHD (RR = 2.14, P = 0.0001). On the contrary, transplants of cord blood stem cells were characterized by a very low incidence of C-GVHD, with only 1 child out of 32 presenting this complication (RR = 0.07, P = 0.001).
Causes of death and transplant-related mortality
Overall, 191 (27%) out of the 696 patients analyzed died; 146 (28%) belonged to the group of 523 subjects without C-GVHD, while 45 (26%) belonged to the 173 children with C-GVHD.
Details on the causes of death for patients with and without C-GVHD are reported in Table   3 . Disease progression was the main cause of death in 102 patients, while 89 children died due to transplant-related causes. In patients with C-GVHD, we observed a significantly higher percentage of transplant-related deaths (69%) as compared to subjects without C-GVHD (40%), and a lower percentage of deaths due to disease progression (31% vs. 60%, P = 0.0006). In the group of children who had C-GVHD, this complication was indicated as the primary cause of death in 11 out of the 31 patients who died due to transplant-related causes (35%), so that 6% of the 173 patients with C-GVHD died because of this complication.
In the 11 cases where C-GVHD was reported as the main cause of death, the ultimate cause of death was: bronchiolitis obliterans in 4 cases, cytomegalovirus interstitial pneumonia in 1 case, bacterial pneumonia in 1 case, other bacterial infections in 3 cases, hemorrhagic complications in 1 case and multi-organ failure in 1 case.
For patients treated for non-malignant disorders, the cumulative probability of TRM was 13% (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) for children without C-GVHD, 5% (0-15) for those with the limited form of the disease and 64% (11-100) for those with extensive C-GVHD (P = 0.016). For subjects treated for malignant diseases, the cumulative probability of TRM was 9% (5-13) for children without C-GVHD, 15% (5-25) for those with limited disease and 24% (12-36) for those with extensive C-GVHD ( P = 0.036).
Relapse probability
One hundred and twenty seven (28%) of the 450 children who received HSCT for treatment of hematological malignancy experienced disease relapse. Analyzing the risk of relapse according to C-GVHD occurrence, we observed that the 6-year cumulative relapse probability was significantly lower (P = 0.0001) in children with C-GVHD, being 16% (10-22) as compared to a value of 39% (33-45) in patients without C-GVHD (Figure 3 ). Table 4 shows the results of univariate and multivariate analysis of the probability of relapse in the 450 children affected by hematological malignancies. C-GVHD confirmed its protective effect against relapse also in multivariate analysis (RR = 0.32, P = 0.0001, for patients with C-GVHD vs. those without C-GVHD).
Stratifying the analysis by type of malignancy, we observed that the GVL effect associated with C-GVHD was stronger in the 268 patients with ALL. In fact, the relapse probability for children with ALL and C-GVHD was 14% (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , as compared to the 47% (39-54) For 
patients with AML, the relapse probability was identical (29%) in both groups of patients. Among the 20 children with MDS, development of C-GVHD was associated with a lower relapse probability, even though the advantage was not statistically significant (0% vs. 36%, P = 0.053). Since only 3 out of the 28 children with CML relapsed, it was impossible to analyze the role of C-GVHD on leukemia recurrence in this group of patients.
Survival and disease-free survival
Overall, 482 of the 696 patients analyzed (69%) are alive and disease-free, with a cumulative probability of DFS of 67% (63-71). Figure 4 shows the 6-year cumulative probability of DFS for patients with either nonmalignant disorders (Figure 4 , top) or hematological malignancies (Figure 4, bottom) , respectively. For children with non-malignant diseases, no statistically significant difference was observed for DFS between patients without or with C-GVHD (85% vs. 77%, P = NS), this finding being due to the fact that most of patients with C-GVHD had the limited form of the disease. On the contrary, considering children transplanted for malignant diseases, patients who developed C-GVHD had a significantly better DFS, as compared to children without C-GVHD (68% vs. 54%, P = 0.0013). Table 5 summarizes the results of univariate and multivariate analysis of DFS probability for the 450 children affected by malignant diseases. As for relapse, the positive impact of C-GVHD on DFS was confirmed also in multivariate analysis, where this variable was associated with a relative risk of DFS of 2.07 (P = 0.0001).
As already observed for relapse probability, also for DFS the favorable influence of C-GVHD was observed only for children with ALL, where the cumulative probability of DFS was 74% (64-83) for patients developing C-GVHD and 47% (38-53) for children without C-GVHD (P = 0.0001), while the effect on other hematological malignances was non- 13 significant. In fact, in the 99 patients with AML the DFS probability was 59% (36-82) for children with C-GVHD and 68% for those without C-GVHD (P = N.S.) and in the 28 children with CML it was 64% (35-92) and 71% (44-97) for subjects with and without C-GVHD, respectively (P = N.S.). Finally, also considering the 20 children with MDS, the outcome of patients with and without C-GVHD was similar, DFS being 67% (36-97) and 64% (35-92), respectively (P = N.S.).
For
Discussion
C-GVHD remains a substantial problem of allogeneic HSCT. Several studies, published in the last years, introduced the notion that recipient age is a major risk factor for the development of C-GVHD and that children have a lower probability of presenting this complication. [4] [5] [6] However, this information, as well as our clinical knowledge of C-GVHD and of its risk factors, are primarily based on results of analyses performed in adults.
In our study, conducted on the largest pediatric population reported so far, we observed a cumulative probability of C-GVHD of 27%, which is similar to those ranging from 22 to 29%
reported by three other analyses conducted on smaller cohorts of pediatric patients in the last years. [13] [14] [15] This probability is nearly half of the estimated probability of 40-50% described in adults. [4] [5] [6] In our group of patients younger than 18 years, older patient and donor age were predictive of a higher risk of C-GVHD both in univariate and in multivariate analysis. On the contrary, the type of donor and of GVHD prophylaxis was not predictive of the development of this complication. In multivariate analysis, also other factors, such as the female donor/male recipient combination, a diagnosis of malignant disease, the use of TBI and, as expected, previous grade-II-IV acute GVHD, were characterized by a significantly higher risk of C-GVHD. Furthermore, in agreement with the observation of Rocha et al., 30 use of cord blood progenitor cells was confirmed to be characterized by a very low probability of C-GVHD. By contrast, we could not confirm the observation of an increased risk of C-GVHD in subjects receiving peripheral blood stem cells. 8, 9 This was possibly due to the limited number of patients receiving peripheral blood stem cells.
Our study confirms previously published reports documenting that male patients given transplantation from a female donor experience more GVHD, 6 an observation that has been biologically explained hypothesizing that male antigens (i.e. H-Y) not shared by females are recognized and attacked by the donor's immune system. 31,32 However, our
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From data are particularly intriguing, as most female donors were young and, thus, not sensitized towards male antigens by previous pregnancies. Furthermore, even if evaluated on a limited number of subjects, parity of female donors was not a risk factor for C-GVHD development, this suggesting that even a primary immune response towards these molecules may produce C-GVHD.
Children with non-malignant disorders had a reduced risk of developing C-GVHD. Several factors may be considered to explain this observation. Since children with these diseases do not benefit at all from GVHD, it is reasonable to hypothesize that the most effective pharmacological strategies for both GVHD prevention and therapy of acute GVHD were employed in these patients. Moreover, it has been already reported that these patients can have a mixed chimerism, [33] [34] [35] and this condition is associated with reduced susceptibility to GVHD, probably through mechanisms of central tolerance with negative selection of both host-reactive and donor-reactive T-cells. 36 Finally, some of the children with non-malignant disorders (i.e. those with aplastic anemia or with congenital immunodeficiencies) were given less intensive preparative regimens and it has been hypothesized that the cytokine storm, which is dependent on the intensity of the conditioning regimen, triggers development of GVHD. 37 In this regard, the finding of an increased risk of C-GVHD in children given TBI as part of the preparative regimen is also of particular interest.
Moreover, since it has been suggested a relevant role of recipient's thymus in promoting tolerance of donor cells, we speculate that the higher risk of C-GVHD in children given TBI can be partly explained by a radiation-induced damage to thymic epithelial cells.
38-40
We also found an increased risk of C-GVHD in patients transplanted from an older donor.
The detrimental effect of increased donor age on C-GVHD has been recently reported in a cohort of patients given HSCT from unrelated volunteers. 41 The biological mechanisms accounting for this effect of donor age remain unclear and deserve further investigation.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Considerable experimental and clinical data suggest a role of the immune system in controlling cancer and, particularly, leukemia, through the GVL effect. 12, [42] [43] [44] [45] In our study, we document a strong protective effect of C-GVHD against relapse in children with ALL, while the advantage was lower and not statistically significant for patients with MDS and absent for those with AML. Moreover, in children with ALL, the increased TRM associated with C-GVHD was largely offset by the impressive reduction in relapse probability, thus resulting in a significantly better survival and DFS.
Despite a beneficial GVL effect against relapse, C-GVHD remains a major determinant of poor long-term outcome and of impaired quality of life after allogeneic HSCT. 2 For this reason, several efforts have been made to identify factors having an unfavorable prognostic significance, in order to select subjects with higher risk of either death or invalidating sequelae (as severe joint contractures requiring physical therapy, impairment of lung function, keratoconjunctivitis sicca with corneal lesions, malnutrition due to gastrointestinal involvement), who need to be treated promptly and more intensively.
46-49
Over the last years, new drugs and different treatment modalities have been developed for patients with C-GVHD, 50 even though the optimal treatment is still controversial and no single therapy has been demonstrated to be superior and most effective.
51
In our study population, subjects developing C-GVHD had a significantly higher TRM, as compared to those without the disease, even though only 6% of children with C-GVHD died directly or indirectly because of this complication. The negative effect of C-GVHD was particularly evident in patients with the extensive form of the disease and for those affected by non-malignant disorders. These observations emphasize the need for a more effective prophylaxis for patients transplanted with the aim of curing non-malignant disorders and a more effective treatment for those with extensive GVHD and/or with poor prognostic clinical features.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Our data document that children have a lower incidence of C-GVHD, as compared to adults. Use of cord blood stem cells and of conditioning regimens without TBI, as well better strategies for preventing acute GVHD occurrence, could further decrease the risk of this complication. We provide evidence for a strong anti-leukemia effect of C-GVHD for ALL, but not for other hematological malignances. Despite an increased TRM, probability of DFS in ALL was not impaired by the occurrence of this complication. To calculate the probability of continuing C-GVHD, C-GVHD resolutions were considered as events, while patients whose C-GVHD did not resolve were censored at time of last follow-up or of death.
To calculate the probability of death with C-GVHD, only deaths with active C-GVHD were considered events, while patients whose C-GVHD resolved were censored at time of last follow-up or of death. . 6-year probability of disease-free survival (DFS) according to the development of C-GVHD, for patients affected by non-malignant disorders (top) and for those affected by hematological malignancies (bottom). The difference was not statistically significant for non-malignant disorders while, in the group of patients affected by malignant diseases, the advantage for subjects with C-GVHD was statistically significant (P = 0.0013).
